8-K: IO Biotech Announces Business Highlights and Provides Clinical Trial Updates

IO Biotech reports business highlights for Q4 2024, including updates on Cylembio's clinical trials and cash position.

Summary

• IO Biotech announced business highlights for the fourth quarter of 2024.
• The company is preparing to submit a Biologics License Application (BLA) for Cylembio to the FDA by the end of 2025.
• Enrollment in the Phase 3 trial for Cylembio completed in December 2023 with 407 patients.
• The readout of the primary endpoint for the Phase 3 trial, progression-free survival (PFS), is now expected in the third quarter of 2025.
• Enrollment in the Phase 2 basket trial of Cylembio as neoadjuvant/adjuvant treatment for resectable melanoma or head and neck cancer is complete, with initial data anticipated in the second half of 2025.
• The company's cash and cash equivalents at the end of Q4 2024 were approximately $60 million.
• IO Biotech secured up to $57.5 million in debt financing from the European Investment Bank (EIB).
• The company expects that the capital drawn from the three committed tranches of the EIB debt facility will extend the cash runway into the second quarter of 2026.
• IO Biotech will present at the TD Cowen's 45th Annual Health Care Conference on March 5, 2025.
• The company adopted Cylembio as the US brand name for its IO102-IO103 lead investigational therapeutic cancer vaccine.
• The company plans to submit an Investigational New Drug Application (IND) for IO112 to the FDA in 2025.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive. While there is a delay in the Phase 3 trial readout, the company is progressing with other clinical trials, has secured funding, and is preparing for a BLA submission. The delay is a concern, but the overall outlook remains optimistic.

Positives

• The company is on track to submit a BLA for Cylembio to the FDA by the end of 2025.
• Enrollment in the Phase 3 trial for Cylembio completed ahead of schedule.
• Enrollment is complete in the Phase 2 basket trial of Cylembio, with initial data expected in the second half of 2025.
• IO Biotech secured up to $57.5 million in debt financing from the EIB, extending the cash runway into the second quarter of 2026.
• The company met the primary endpoint of overall response rate (ORR) in its Phase 2 basket trial IOB-022/KN-D38 investigating Cylembio given in combination with pembrolizumab as first-line treatment for SCCHN.
• Promising activity was demonstrated in the first-line treatment for metastatic non-small cell lung cancer (NSCLC) with approximately half of patients having no disease progression at 12 months.
• New preclinical data for IO112, the company's second immune-modulatory therapeutic cancer vaccine candidate targeting Arginase-1, was published in the Journal for ImmunoTherapy of Cancer.

Risks

• The readout of the primary endpoint for the Phase 3 trial is delayed to the third quarter of 2025 due to a slowing in the rate of PFS events.
• The preliminary statement of the company's cash and cash equivalents as of December 31, 2024 is subject to change, and the company's actual cash and cash equivalents as of December 31, 2024 may differ materially from this preliminary estimate.

Future Outlook

IO Biotech anticipates an exciting 2025 with the primary endpoint readout of the Phase 3 trial expected in Q3 2025 and plans to submit a BLA to the FDA by the end of the year, with a potential US launch in 2026, pending positive data and FDA approval.

Management Comments

• With the primary endpoint readout of our pivotal Phase 3 trial investigating Cylembio in combination with pembrolizumab for patients with advanced melanoma now expected in the third quarter, we expect 2025 could be an exciting year for IO Biotech, said Mai-Britt Zocca, PhD, President and CEO of IO Biotech.
• Pending positive data, we expect to submit a BLA to the US FDA by the end of the year and a potential launch in the US in 2026.
• There is still a significant unmet medical need for new treatment options for patients suffering from advanced melanoma, metastatic head and neck cancer, and metastatic lung cancer.
• The full IO Biotech team is proud to be leading the next frontier of immune-oncology with the development of therapeutic cancer vaccines for these and other difficult-to-treat cancers.
• Our investigational therapeutic cancer vaccines are designed with a unique mechanism of action capable of targeting both immune-suppressive cells in the tumor microenvironment (TME) and cancer cells, which have demonstrated promising activity when combined with an anti-PD-1 therapy.
• We look forward to potentially commercializing a first-in-class immune-modulatory, off-the-shelf therapeutic cancer vaccine that could be delivered to cancer patients when treatment is needed.

Industry Context

IO Biotech is focused on developing immune-modulatory therapeutic cancer vaccines, a growing area in the biopharmaceutical industry. The company's approach targets both tumor cells and immune-suppressive cells in the tumor microenvironment, which could offer a novel treatment option compared to existing therapies like anti-PD-1 monotherapy.

Comparison to Industry Standards

• IO Biotech's approach of combining Cylembio with pembrolizumab (KEYTRUDA) is similar to strategies employed by other companies in the immuno-oncology space, such as Bristol Myers Squibb with Opdivo (nivolumab) combinations.
• The focus on therapeutic cancer vaccines aligns with companies like Moderna and BioNTech, which are also exploring mRNA-based vaccines for cancer treatment.
• The $57.5 million debt financing from the EIB is a common funding mechanism for European biotech companies, similar to arrangements seen with other firms like Genmab and argenx.

Stakeholder Impact

• Shareholders: The delay in the Phase 3 trial readout may negatively impact short-term stock performance, but the overall progress and funding could be viewed positively.
• Patients: The development of Cylembio offers potential new treatment options for advanced melanoma, head and neck cancer, and lung cancer.
• Employees: The company's progress and funding provide job security and opportunities for growth.
• Merck: The collaboration with Merck for pembrolizumab (KEYTRUDA) continues to be a key aspect of IO Biotech's clinical trials.

Next Steps

• Submit a Biologics License Application (BLA) for Cylembio to the FDA by the end of 2025.
• Continue clinical development of Cylembio in the Phase 2 solid tumor basket trial.
• Submit an Investigational New Drug Application (IND) for IO112 to the FDA in 2025.
• Present at the TD Cowen's 45th Annual Health Care Conference on March 5, 2025.
• Await the readout of the primary endpoint (PFS) in the Phase 3 trial in the third quarter of 2025.
• Release initial data from the Phase 2 basket trial in the second half of 2025.
• Follow patients in the Phase 2 basket trial IOB-022/KN-D38, with longer-term data expected in the second half of 2025.

Key Dates